Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Yang, Zu Yao ^a   Yuan, Jin Qiu ^a   Di, Meng Yang ^a   Zheng, Da Yong ^b   Chen, Jin Zhang ^b   Ding, Hong ^b   Wu, Xin Yin ^a   Huang, Ya Fang ^a   Mao, Chen ^a   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEMCITABINE; PLACEBO; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER CONTROL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TIME TO PROGRESSION; TOXIC HEPATITIS; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; MORTALITY; PANCREATIC NEOPLASMS; TIME; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874620350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057528     Document Type: Article

References (45)

1. Bond-Smith G, Banga N, Hammond TM, Imber CJ, (2012) Pancreatic adenocarcinoma. BMJ 344: e2476.
2. Lowenfels AB, Maisonneuve P, (2006) Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 197-209.
3. Anderson K MT, Silverman DT (2006) Cancer of the pancreas. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. 3rd ed. Oxford University Press.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
5. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592.
6. Feliu J, Borrega P, Leon A, Lopez-Gomez L, Lopez M, et al. (2011) Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemother Pharmacol 67: 215-221.
7. Cascinu S, Graziano F, Catalano G, (1999) Chemotherapy for advanced pancreatic cancer: it may no longer be ignored. Ann Oncol 10: 105-109.
8. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
9. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, et al. (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275.
10. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, et al. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952.
11. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516.
12. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, et al. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783.
13. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, et al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94: 902-910.
14. Miller VA, Kris MG, (2000) Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 27: 3-10.
15. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, et al. (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12: 610-621.
16. Perez-Soler R, Saltz L, (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23: 5235-5246.
17. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, et al. (2003) Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 11: 305-309.
18. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET, (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9: 1469-1473.
19. Xiong HQ, (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54 (Suppl 1): S69-77.
20. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, et al. (2004) The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29: e1-8.
21. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
22. Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, et al. (2012) Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol 23: 1919-1925.
23. Cheng YJ, Bai CM, Zhang ZJ, (2010) Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 32: 421-423.
24. Munoz Llarena A, Mane J, Lopez-Vivanco G, Ruiz de Lobera A, Sancho A, et al. (2011) Gemcitabine (G) fixed-dose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC). Available: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71207. Accessed 7 November 2012.
25. Philip PA, Goldman BH, Ramanathan RK, Lenz HJ, Lowy AM, et al. (2012) Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). Available: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87986. Accessed 7 November 2012.
26. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, et al. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237.
27. Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 8. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
28. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. Bmj 327: 557-560.
30. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315: 629-634.
31. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I, (2006) The case of the misleading funnel plot. Bmj 333: 597-600.
32. Ardavanis A, Kountourakis P, Karagiannis A, Doufexis D, Tzovaras AA, et al. (2009) Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer. Anticancer Res 29: 5211-5217.
33. Bengala C, Sternieri R, Malavasi N, Ponti G, Bertolini F, et al. (2009) Phase II trial of erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer (APC). Available: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10332. Accessed 7 November 2012.
34. Okusaka T, Furuse J, Funakoshi A, Ioka T, Yamao K, et al. (2010) Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102: 425-431.
35. Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, et al. (2007) Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 60: 295-303.
36. Stuebs P, Habermann P, Zierau K, Schuette K, Fahlke J, et al. (2010) First-line therapy for advanced pancreatic cancer with gemcitabine and docetaxel versus gemcitabine and erlotinib: A multivariate matched pair analysis. Available: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52331. Accessed: 7 November 2012.
37. Milella M, Vaccaro V, Sperduti I, Bria E, Gelibter A, et al. (2010) Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC). Available: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=51951. Accessed: 7 November 2012.
38. Kim GP, Foster NR, Salim M, Flynn PJ, Moore DF, et al. (2011) Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma. Available: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82619. Accessed: 7 November 2012.
39. Modiano M, Keogh GP, Manges R, Stella PJ, Milne G, et al. (2012) Apricot-P: A randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas. Available: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87740. Accessed: 7 November 2012.
40. Boeck S, Vehling-Kaiser U, Waldschmidt D, Kettner E, Marten A, et al. (2010) Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs 21: 94-100.
41. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, et al. (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14: 97-104.
42. Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, et al. (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17: 1779-1785.
43. Stathopoulos GP, Androulakis N, Souglakos J, Stathopoulos J, Georgoulias V, (2008) Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 28: 1303-1308.
44. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, et al. (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645.
45. Stathopoulos GP, Mavroudis D, Tsavaris N, Kouroussis C, Aravantinos G, et al. (2001) Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12: 101-103.